Howard Berman's departure as Executive Chairman of Coya Therapeutics, Inc. was reported, effective April 1, 2026; the filing names no successor. As of November 6, 2026, Coya Therapeutics, Inc. has reported 2 leadership change filings to the SEC under Item 5.02 of Form 8-K, from April 2, 2026 to August 7, 2026, naming 2 appointments and 1 departure (Form 8-K, April 2, 2026).
30 companies changed executives this week.
Companies that just changed executives, and the new executive. Before you unlock: the company, the change and what is inside. After: the executive named with their role, how to reach the company, and a person's email only when we found one.
| John Hancock Comvest Private Income Fund | named a new Chief Financial Officer | |
| Bain Capital Specialty Finance, Inc. | named a new Director | |
| Azora Therapeutics, Inc. (DE) | named a new Director | |
| LASE Corp. | named a new Director | |
| Century Communities, Inc. | named a new Executive Chairman |
Sell to companies like Coya Therapeutics, Inc? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Coya Therapeutics, Inc. reported changes in 2 filings among its directors and officers to the SEC on Form 8-K, Item 5.02, from 2026-04-02 to 2026-08-07. They name 2 people, with 2 appointments and 1 departure. Every row below is cited to the filing it comes from, and this page adds each new change as Coya Therapeutics, Inc. files it.
Also on the record for Coya Therapeutics, Inc.
| Date | Record | Figure | Our page | Source |
|---|---|---|---|---|
| July 27, 2026 | Stake report, Schedule 13G/A, by Orin Hirschman | 3.3% of the class | 5%+ stakes | Source |
| March 12, 2026 | Stake report, Schedule 13G, by Dr. Reddy's Laboratories, Inc. | 9.7% of the class | 5%+ stakes | Source |
| January 30, 2026 | Stake report, Schedule 13G/A, by The Vanguard Group | 4.29% of the class | 5%+ stakes | Source |
| January 28, 2026 | Stake report, Schedule 13G/A, by Orin Hirschman | 5.3% of the class | 5%+ stakes | Source |
Selling to them or working with them? See who runs Coya Therapeutics, Inc. now and the warning signs.
Free to see. No signup.
Keep reading
More on Coya Therapeutics, Inc. and the records around it.
Coya Therapeutics, Inc. elsewhere on the record
- 5%+ stake filings Jul 2026
- Who owns it
Companies that share a holder
- Orin Hirschman also filed stake reports on 46 other companies: ASPEN AEROGELS, INC. (Oct 2026), Bionano Genomics, Inc. (Oct 2026), FENNEC PHARMACEUTICALS INC. (Oct 2026)
- The Vanguard Group also filed stake reports on 2384 other companies: BellRing Brands, Inc. (Sep 2026), CAL-MAINE FOODS INC (Sep 2026), FTAI Aviation Ltd. (Sep 2026)
Watch Coya Therapeutics, Inc.
Get an email when Coya Therapeutics, Inc. files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on Coya Therapeutics, Inc.?
Example from a real report (our sample on Target): “The Q2 2026 earnings report, published August 19, 2026, showed adjusted EPS of $2.46 against an expected $2.33” Source: CNBC
A Full Report on Coya Therapeutics, Inc.: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on Coya Therapeutics, Inc. covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
6 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Timeline
| Filed | In / out | Person | Role | Effective | Source |
|---|---|---|---|---|---|
| 2026-08-07 | In | 8-K/A, 2026-08-07 | |||
| 2026-04-02 | Out | Executive Chairman | 2026-04-01 | 8-K, 2026-04-02 | |
| 2026-04-02 | In | Director | 2026-04-01 | 8-K, 2026-04-02 |
Who leads Coya Therapeutics, Inc., as last reported?
For each role that changed in the filings below, the most recent change reported. A role that did not change in these filings is not listed.
- Director: Mark H. Pavao, appointed, effective 2026-04-01 (filed 2026-04-02).
- Executive Chairman: Howard Berman, departure reported, effective 2026-04-01 (filed 2026-04-02). No successor is named in these filings.
New leaders reset buying decisions — get the Full Report on Coya Therapeutics, Inc.: who runs it, how the money works and what to watch, every claim linked to its source.
Get the Full ReportFind people with the same kind of experience as the Executive Chairman at Coya Therapeutics, Inc., with the record behind each one.
Find candidates like Executive Chairman at Coya Therapeutics, Inc.Every change, in the filing's words
Appointed: Mark H. Pavao
This Amendment is being filed solely to report that on August 6, 2026, the Board, upon the recommendation of the Nominating and Corporate Governance Committee, appointed Mr. Pavao to the Audit Committee of the Board, effective immediately.
- Effective upon such appointment to the Audit Committee, the members of the Audit Committee are Dr. Dov Goldstein (Chair), Dr. Ann Lee, Dieter Weinand and Mark H. Pavao.
Departing: Howard Berman, Executive Chairman, effective 2026-04-01
On March 29, 2026, Dr. Howard Berman resigned from the board of directors (the "Board") of Coya Therapeutics, Inc. (the "Company") and from his position as Executive Chairman, each effective as of April 1, 2026.
Appointed: Mark H. Pavao, Director, effective 2026-04-01
On April 1, 2026, upon the recommendation of the Nominating and Corporate Governance Committee, the Board appointed Mark H. Pavao to serve as an independent director, effective April 1, 2026, to fill the vacancy created by Dr. Berman's resignation.
- In connection with Dr. Berman's resignation as Executive Chairman, the Company and Dr. Berman entered into a Separation and General Release Agreement (the "Separation Agreement").
- The Separation Agreement further provides that Dr. Berman is not entitled to any additional compensation or severance other than as expressly set forth therein and that the Separation Agreement supersedes any obligations of the Company under his prior employment agreement.
- In addition, the Separation Agreement contains a general release of claims in favor of the Company and its affiliates, customary non-disparagement provisions, and an affirmation of Dr. Berman's continuing obligations under existing confidentiality and restrictive covenant agreements.
- Mr. Pavao was appointed as a Class III director, with a term expiring at the Company's 2028 annual meeting of stockholders and until his successor is duly elected and qualified or until his earlier resignation or removal.
- In connection with his appointment, Mr. Pavao will be granted an option to purchase 10,000 shares of the Company's common stock with an exercise price equal to the closing price on Nasdaq of the Company's common stock on the date of grant, with all options vesting on the one-year anniversary of the date of the grant, subject to Mr. Pavao's continued service to the Company.
Tools for this story
Each opens in a new tab, filled in for Coya Therapeutics, Inc.. With no account yet, you sign up free and land on the result.
Where this comes from
A public company must file a current report on Form 8-K with the SEC within four business days when a director leaves or is elected, or when its chief executive, chief financial, chief accounting or chief operating officer, or another named executive, departs or is appointed. That disclosure goes under Item 5.02 of the report.
Every change on this page is taken from one of those filings and quoted in the company's own words, with a link to the filing, so it can be checked at the source. Where a filing names the person, the role and the date a change takes effect, they are shown beside the quote. Where it does not, the quote stands on its own. A filing states what changed; it rarely states why, and neither does this page.